Elutia has signed a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11 million. Elutia will receive $8 million in cash at closing, along with up to $3 million in technology transfer and commercial milestone payments over the next 18 months. The deal is expected to close in the second half of 2026, subject to customary closing conditions. The divestiture aligns with Elutia's strategy to focus resources on NXT-41x, its antibiotic-eluting biomatrix in development for the $1.5 billion U.S. plastic and reconstructive surgery market. Proceeds further strengthen Elutia's balance sheet without equity dilution and provide additional capital to support a planned commercial launch in 2027. Elutia stock closed Thursday at $0.95, down 1.03%, and fell a further 3.52% in pre-market trading to $0.91.
Elutia Inc.Elutia sells SimpliDerm for up to $11M, strengthening balance sheet without dilution and funding NXT-41x launch.